Peginterferon Alfa‑2b
| Product Overview | |
| Generic Name | Peginterferon Alfa‑2b |
| Brand Name(s) | ViraferonPeg, PegIntron |
| Form | Injectable solution – vials |
| Strength | 150 μg vial / 1.5 μg/kg |
| Therapeutic Class | Antiviral – interferon alpha |
| ATC Code | L03AB10 |
| Manufacturing & Regulatory | |
| Manufacturer | Biotechnica DWC, Hayashibara |
| Country | India, Japan, USA |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Manufacturer provides standard SDS (biologic/aqueous injectable) |
| CTD Summary | Full CTD dossier proprietary; available under commercial agreement/license |
Description
Indications & Usage Summary: Peginterferon Alfa‑2b is a pegylated recombinant interferon alpha-2b used historically to treat chronic hepatitis C virus (HCV) infection, often in combination with ribavirin. It also has antiviral activity in conditions like Kaposi’s sarcoma, melanoma, and hairy-cell leukemia.
